文献速递冠心病

新一代药物洗脱支架在急性心肌梗死女性中的长期安全性与疗效:WIN-DES协作研究

Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.
PubMed 文献 · JAMA Cardiol · 2017-01-01

该研究基于26项随机临床试验的个体患者数据,分析4373例急性冠脉综合征女性,其中2176例为急性心肌梗死。在新一代药物洗脱支架(DES)与早期DES的对比中,新一代DES与3年随访时死亡、心肌梗死或靶病变血运重建复合终点风险降低相关(14.9% vs 18.4%),以及明确或可能的支架血栓风险降低相关(1.4% vs 4.0%)。

要点

  • 急性心梗女性使用新一代DES,3年死亡、心梗或靶病变血运重建风险低于早期DES。
  • 新一代DES明确或可能支架血栓风险显著低于早期DES。
  • 绝对获益从UA到NSTEMI再到STEMI呈递增趋势。

核心结论

  • 在急性心肌梗死女性中,新一代DES相较于早期DES在3年内具有一致且持久的获益。
  • 获益幅度随急性冠脉综合征严重程度增加而增大。

研究设计与样本

  • 国际多中心协作的个体患者水平数据分析,纳入26项DES随机临床试验中的女性患者。
  • 急性心梗包括非ST段抬高型心肌梗死(NSTEMI)或ST段抬高型心肌梗死(STEMI)。
  • 干预为随机分配至早期DES(西罗莫司或紫杉醇洗脱支架)或新一代DES(依维莫司、佐他莫司或生物莫司洗脱支架)。

主要发现

  • 在急性心梗女性中,新一代DES与死亡、心肌梗死或靶病变血运重建复合终点风险降低相关(14.9% vs 18.4%;绝对风险差-3.5%;需治疗人数[NNT] 29;校正风险比0.78;95%CI 0.61-0.99)。
  • 在急性心梗女性中,新一代DES与明确或可能支架血栓风险降低相关(1.4% vs 4.0%;绝对风险差-2.6%;NNT 46;校正风险比0.36;95%CI 0.19-0.69)。
  • 在从UA到NSTEMI再到STEMI的转变中,新一代DES的绝对获益呈梯度增加(死亡、心梗或靶病变血运重建:UA -0.5% [NNT 222];NSTEMI -3.1% [NNT 33];STEMI -4.0% [NNT 25];明确或可能支架血栓:UA -0.4% [NNT 278];NSTEMI -2.2% [NNT 46];STEMI -4.0% [NNT 25])。

临床怎么用

  • 对于接受经皮冠状动脉介入治疗的急性心肌梗死女性,优先选择新一代DES以降低长期不良事件风险。
  • 急性冠脉综合征严重程度越高(如STEMI),使用新一代DES的绝对获益可能越大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Women with acute myocardial infarction (MI) undergoing mechanical reperfusion remain at increased risk of adverse cardiac events and mortality compared with their male counterparts. Whether the benefits of new-generation drug-eluting stents (DES) are preserved in women with acute MI remains unclear. OBJECTIVE: To investigate the long-term safety and efficacy of new-generation DES vs early-generation DES in women with acute MI. DESIGN, SETTING, AND PARTICIPANTS: Collaborative, international, individual patient-level data of women enrolled in 26 randomized clinical trials of DES were analyzed between July and December 2016. Only women presenting with an acute coronary syndrome were included. Study population was categorized according to presentation with unstable angina (UA) vs acute MI. Acute MI included non-ST-segment elevation MI (NSTEMI) or ST-segment elevation MI (STEMI). INTERVENTIONS: Randomization to early- (sirolimus- or paclitaxel-eluting stents) vs new-generation (everolimus-, zotarolimus-, or biolimus-eluting stents) DES. MAIN OUTCOMES AND MEASURES: Composite of death, MI or target lesion revascularization, and definite or probable stent thrombosis at 3-year follow-up. RESULTS: Overall, the mean age of participants was 66.8 years. Of 11 577 women included in the pooled data set, 4373 (37.8%) had an acute coronary syndrome as clinical presentation. Of these 4373 women, 2176 (49.8%) presented with an acute MI. In women with acute MI, new-generation DES were associated with lower risk of death, MI or target lesion revascularization (14.9% vs 18.4%; absolute risk difference, -3.5%; number needed to treat [NNT], 29; adjusted hazard ratio, 0.78; 95% CI, 0.61-0.99), and definite or probable stent thrombosis (1.4% vs 4.0%; absolute risk difference, -2.6%; NNT, 46; adjusted hazard ratio, 0.36; 95% CI, 0.19-0.69) without evidence of interaction for both end points compared with women without acute MI (P for interaction = .59 and P for interaction = .31, respectively). A graded absolute benefit with use of new-generation DES was observed in the transition from UA, to NSTEMI, and to STEMI (for death, MI, or target lesion revascularization: UA, -0.5% [NNT, 222]; NSTEMI, -3.1% [NNT, 33]; STEMI, -4.0% [NNT, 25] and for definite or probable ST: UA, -0.4% [NNT, 278]; NSTEMI, -2.2% [NNT, 46]; STEMI, -4.0% [NNT, 25]). CONCLUSIONS AND RELEVANCE: New-generation DES are associated with consistent and durable benefits over 3 years in women presenting with acute MI. The magnitude of these benefits appeared to be greater per increase in severity of acute coronary syndrome.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Giustino G, Harari R, Baber U, et al. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017. PMID: 28658478. doi:10.1001/jamacardio.2017.1978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。